Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

Orchestra BioMed (NASDAQ:OBIO) had its price objective lowered by research analysts at B. Riley Financial from $12.00 to $10.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s price objective points to a potential upside of 148.45% from the company’s previous close.

A number of other equities analysts have also weighed in on OBIO. Weiss Ratings lowered shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Orchestra BioMed in a research note on Thursday, May 14th. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Barclays upped their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.60.

Orchestra BioMed Stock Up 1.1%

NASDAQ OBIO traded up $0.05 on Tuesday, reaching $4.03. The company had a trading volume of 462,734 shares, compared to its average volume of 215,212. The firm has a market capitalization of $241.02 million, a price-to-earnings ratio of -4.15 and a beta of 0.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The company’s fifty day moving average is $4.28 and its 200-day moving average is $4.27.

Orchestra BioMed (NASDAQ:OBIO) last announced its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. On average, research analysts forecast that Orchestra BioMed will post -1.62 earnings per share for the current fiscal year.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, Director Eric S. Fain acquired 20,000 shares of Orchestra BioMed stock in a transaction dated Thursday, May 14th. The stock was bought at an average cost of $4.13 per share, for a total transaction of $82,600.00. Following the purchase, the director directly owned 91,709 shares in the company, valued at approximately $378,758.17. This represents a 27.89% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jason Aryeh acquired 8,971 shares of Orchestra BioMed stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $3.90 per share, with a total value of $34,986.90. Following the completion of the purchase, the director owned 117,453 shares in the company, valued at approximately $458,066.70. The trade was a 8.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 43,971 shares of company stock worth $179,337 in the last three months. Insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Orchestra BioMed

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Orchestra BioMed during the 4th quarter worth about $38,000. Creative Planning bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $40,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $45,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $50,000. Finally, Virtu Financial LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at about $57,000. 53.20% of the stock is currently owned by institutional investors and hedge funds.

Key Orchestra BioMed News

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 per share, signaling confidence from management and adding to the bullish insider-buying trend. SEC filing
• Positive Sentiment: Insider David P. Hochman also purchased 5,000 shares at $3.77, adding another vote of confidence from a company insider. SEC filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while slightly raising near-term EPS estimates for 2026 and 2027, which may reassure investors that Wall Street still sees meaningful upside. Analyst coverage
• Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which could provide a catalyst if investors look for updates on pipeline progress or partnerships. Conference announcement
• Neutral Sentiment: Orchestra BioMed’s latest earnings showed a smaller-than-expected loss per share, but revenue remained well below estimates, so the report was mixed overall. Earnings report

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.